Skip to content

Second Russian COVID-19 Vaccine to Finish Clinical Trials Upcoming Month: Reports

covid-19 russian vaccine

After the successful launch of the first COVID-19 vaccine by Russian President Vladimir Putin, the second vaccine clinical trials are to be completed in September. It is the world’s first such vaccine against the novel coronavirus. The second COVID vaccine is developed by the Siberian Vektor research center of Russia, says the news agency RIA citing Russia’s watchdog on Friday (1).

In the first phase of the clinical trials, 14 participants were vaccinated, and 43 were vaccinated during the second phase. In the same stage, 43 patients took part in the control group where they received a placebo. As per the Sputnik News, the statement is given by Rospotrebnadzor Russia’s consumer rights protection and human well-being watchdog.

They further added that all participants of the clinical trials are feeling fine. The volunteers experienced sensitivity at the site of injection besides that they did not have any side-effects.

Further Details on COVID-19 Vaccine of Russia

There will be mass testing of the first potential COVID-19 vaccine in the country. It is to get the local regulatory approval, and it would involve more than 40,000 participants. The trails for the vaccine would be overseen by an international research body, as per the project backers.

The potential COVID-19 vaccine called “Sputnik V” is the world’s first vaccine launched for novel coronavirus by the Soviet Union. The authorities of Russia has announced it safe and effective; however, its results are not made public yet. The data are most likely to get published in an academic journal by the end of the month, stated an official.

Russia has received requests of billion of vaccine doses globally. The country can produce 500 million treatments each year through partnerships for manufacturing. As per the reports, Russia is looking for a partnership with India for Sputnik’s production, said Kirill Dmitriev, the CEO of RDIF.

Sputnik V is developed by the Gamaleya Research Institute of Epidemiology and Microbiology, along with the Russian Direct Investment Fund. Notably, the vaccine is not yet been tested in Phase 3 or more extensive clinical trials.